Herpes simplex virus infections remain a serious global health problem and are the leading cause of genital ulcer disease, a major co-factor in the HIV epidemic, and associated with significant morbidity and mortality in newborns born to mothers who are infected. In a recent publication in eLife, Drs. William Jacobs and Betsy Herold of the Albert Einstein College of Medicine have taken a giant step toward developing a viable herpes vaccine. 

X-VAX Technology

X-VAX Technology, Inc.

X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program

Peer-review Articles on the HSV-2 ΔgD vaccine


JCI Insight

The Journal of Infectious Diseases

News articles on the elife PUBLICATION